. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Clin Chem. 2015 Jul 27;61(9):1164–1172. doi: 10.1373/clinchem.2015.241232

Table 3.

Longitudinal associations between increases in biomarkers relative to baseline and cardiotoxicity.

	Risk of cardiotoxicity at the same visit				Risk ofcardiotoxicityat the subsequent visit
	Univariable		Multivariable		Univariable		Multivariable
Biomarker	HR(95%CI)	P	HR(95%CI)	P	HR(95%CI)	P	HR(95%CI)	P
GDF-15	1.80 (1.20-2.69)	0.007	2.16 (1.49-3.13)	<0.001	1.59 (1.06-2.40)	0.02	1.62 (1.07-2.44)	0.01
MPO	1.37 (1.11-1.69)	0.02	1.31 (1.08-1.60)	0.004	1.32 (1.11-1.58)	0.003	1.30 (1.06-1.58)	0.006
PIGF	3.77 (1.43-9.89)	0.04	3.09 (1.24-7.72)	0.008	2.61 (0.95-7.19)	0.08	3.27 (1.19-8.94)	0.01
hsCRP	1.18 (0.97-1.44)	0.07			1.12 (0.88-1.42)	0.19
hsTnl	1.04 (0.91-1.20)	0.30			1.08 (0.96-1.20)	0.14
GaI-3	1.31 (0.86-1.99)	0.14			1.60 (1.12-2.28)	0.04
NT-proBNP	1.13 (0.86-1.49)	0.19			1.07 (0.83-1.38)	0.31
sFIt-1	1.08 (0.54-2.16)	0.41			0.86 (0.49-1.50)	0.31

Data are median (interquartile range) for a log₂ ratio of the biomarker relative to baseline, i.e., for each doubling of the biomarker. All P-value shown are 1-sided.